Article

FDA approves IOL for cataracts and presbyopia

Alcon Inc. has received FDA approval for a lens designed for implantation during cataract surgery in patients with presbyopia (AcrySof IQ ReSTOR +3.0 D).

Huenenberg, Switzerland

-Alcon Inc. has received FDA approval for a lens designed for implantation during cataract surgery in patients with presbyopia (AcrySof IQ ReSTOR +3.0 D). The lens was introduced outside of the United States in 2008.

“The . . . IOL gives my patients a more comfortable reading distance, improved intermediate vision for tasks such as computer work, and excellent distance vision,” said one study investigator, Kerry Solomon, MD, who is professor of ophthalmology, Medical University of South Carolina, Charleston, and medical director, Storm Eye Institute, Mount Pleasant, SC.

The U.S. clinical trials included a 3-month follow-up exam of near, intermediate, and distance visual acuities. The percentage of patients in whom 20/20 or better vision was achieved at all three distances with the lens was nearly fourfold the rate of patients who received the control lens (AcrySof IQ ReSTOR +4.0 D), according to the company. The clinical studies also demonstrated a high rate of patient satisfaction, with more than 95% of patients stating that they would have the lens implanted again, Alcon relayed.

“Advanced-technology IOLs that correct for presbyopia and astigmatism are the fastest-growing IOL segment of cataract surgery,” said Kevin Buehler, senior vice president, global markets, and chief marketing officer, Alcon. “The addition of this new lens meets a growing desire on the part of cataract patients for spectacle independence after cataract surgery.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.